collection
MENU ▼
Read by QxMD icon Read
search

Anticoagulation

shared collection
195 papers 1000+ followers Anticoagulation for atrial fibrillation, thromboembolism and IHD
By Faye Kehler Family Physician and GP Anesthetist since 1987 interested in all aspects of Medicine
https://www.readbyqxmd.com/read/27347226/newer-oral-anticoagulants-stroke-prevention-and-pitfalls
#1
Anand Patel, Richard P Goddeau, Nils Henninger
Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its use is limited due to fear of hemorrhagic complications, unpredictable anticoagulant effects related to multiple drug interactions and dietary restrictions, a narrow therapeutic window, frequent difficulty maintaining the anticoagulant effect within a narrow therapeutic window, and the need for inconvenient monitoring. Several newer oral anticoagulants have been approved for primary and secondary prevention of stroke in patients with non-valvular atrial fibrillation...
2016: Open Cardiovascular Medicine Journal
https://www.readbyqxmd.com/read/27566810/new-antiplatelet-drugs-and-new-oral-anticoagulants
#2
V Koenig-Oberhuber, M Filipovic
In our daily anaesthetic practice, we are confronted with an increasing number of patients treated with either antiplatelet or anticoagulant agents. During the last decade, changes have occurred that make the handling of antithrombotic medication a challenging part of anaesthetic perioperative management. In this review, the authors discuss the most important antiplatelet and anticoagulant drugs, the perioperative management, the handling of bleeding complications, and the interpretation of some laboratory analyses related to these agents...
September 2016: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/27103740/end-of-the-road-for-heparin-thromboprophylaxis
#3
COMMENT
Lori-Ann Linkins
No abstract text is available yet for this article.
April 21, 2016: Blood
https://www.readbyqxmd.com/read/24335403/new-oral-anticoagulants-and-regional-anaesthesia
#4
REVIEW
H T Benzon, M J Avram, D Green, R O Bonow
The new oral anticoagulants are approved for a variety of clinical syndromes, including the prevention of stroke in atrial fibrillation, acute coronary syndromes, treatment of venous thromboembolism (VTE), and prevention of venous thrombosis after total joint surgery or hip fracture. Published guidelines have differing recommendations on the safe interval between discontinuation of the anticoagulant and performance of neuraxial procedures and between the interventional procedure and redosing of the drug. While two to three half-life intervals might be acceptable in patients who are at high risk for VTE or stroke, an interval of four to six half-lives between discontinuation of the drug and neuraxial injections is probably safer in most patients at low risk of thrombosis...
December 2013: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/20052816/regional-anesthesia-in-the-patient-receiving-antithrombotic-or-thrombolytic-therapy-american-society-of-regional-anesthesia-and-pain-medicine-evidence-based-guidelines-third-edition
#5
Terese T Horlocker, Denise J Wedel, John C Rowlingson, F Kayser Enneking, Sandra L Kopp, Honorio T Benzon, David L Brown, John A Heit, Michael F Mulroy, Richard W Rosenquist, Michael Tryba, Chun-Su Yuan
The actual incidence of neurologic dysfunction resulting from hemorrhagic complications associated with neuraxial blockade is unknown. Although the incidence cited in the literature is estimated to be less than 1 in 150,000 epidural and less than 1 in 220,000 spinal anesthetics, recent epidemiologic surveys suggest that the frequency is increasing and may be as high as 1 in 3000 in some patient populations.Overall, the risk of clinically significant bleeding increase with age,associated abnormalities of the spinal cord or vertebral column, the presence of an underlying coagulopathy, difficulty during needle placement,and an indwelling neuraxial catheter during sustained anticoagulation( particularly with standard heparin or low-molecular weight heparin)...
January 2010: Regional Anesthesia and Pain Medicine
https://www.readbyqxmd.com/read/24946813/new-oral-anticoagulants-a-practical-guide-on-prescription-laboratory-testing-and-peri-procedural-bleeding-management-australasian-society-of-thrombosis-and-haemostasis
#6
H Tran, J Joseph, L Young, S McRae, J Curnow, H Nandurkar, P Wood, C McLintock
New oral anticoagulants (NOAC) are becoming available as alternatives to warfarin to prevent systemic embolism in patients with non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolism. An in-depth understanding of their pharmacology is invaluable for appropriate prescription and optimal management of patients receiving these drugs should unexpected complications (such as bleeding) occur, or the patient requires urgent surgery. The Australasian Society of Thrombosis and Haemostasis has set out to inform physicians on the use of the different NOAC based on current available evidence focusing on: (i) selection of the most suitable patient groups to receive NOAC, (ii) laboratory measurements of NOAC in appropriate circumstances and (iii) management of patients taking NOAC in the perioperative period, and strategies to manage bleeding complications or 'reverse' the anticoagulant effects for urgent invasive procedures...
June 2014: Internal Medicine Journal
https://www.readbyqxmd.com/read/26319422/peri-procedural-management-of-dabigatran-and-rivaroxaban-duration-of-anticoagulant-discontinuation-and-drug-concentrations
#7
MULTICENTER STUDY
Anne Godier, Anne-Céline Martin, Isabelle Leblanc, Elisabeth Mazoyer, Marie-Hélène Horellou, Firas Ibrahim, Claire Flaujac, Jean-Louis Golmard, Nadia Rosencher, Isabelle Gouin-Thibault
BACKGROUND: Peri-procedural management of direct oral anticoagulants (DOAC) is challenging. The optimal duration of pre-procedural discontinuation that guarantees a minimal DOAC concentration ([DOAC]) at surgery is unknown. The usual 48-hour discontinuation might not be sufficient for all patients. OBJECTIVES: To test the hypothesis that a 48-hour DOAC discontinuation is not sufficient to ensure a minimal per-procedural [DOAC], defined as [DOAC]<30ng/mL. To investigate the factors associated with per-procedural [DOAC]...
October 2015: Thrombosis Research
https://www.readbyqxmd.com/read/26890676/endoscopy-in-patients-on-antiplatelet-or-anticoagulant-therapy-including-direct-oral-anticoagulants-british-society-of-gastroenterology-bsg-and-european-society-of-gastrointestinal-endoscopy-esge-guidelines
#8
Andrew M Veitch, Geoffroy Vanbiervliet, Anthony H Gershlick, Christian Boustiere, Trevor P Baglin, Lesley-Ann Smith, Franco Radaelli, Evelyn Knight, Ian M Gralnek, Cesare Hassan, Jean-Marc Dumonceau
The risk of endoscopy in patients on antithrombotics depends on the risks of procedural haemorrhage vs. thrombosis due to discontinuation of therapy. P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor): For low-risk endoscopic procedures we recommend continuing P2Y12 receptor antagonists as single or dual antiplatelet therapy (low quality evidence, strong recommendation);For high-risk endoscopic procedures in patients at low thrombotic risk, we recommend discontinuing P2Y12 receptor antagonists five days before the procedure (moderate quality evidence, strong recommendation)...
April 2016: Endoscopy
https://www.readbyqxmd.com/read/26780747/guidance-for-the-practical-management-of-the-direct-oral-anticoagulants-doacs-in-vte-treatment
#9
REVIEW
Allison E Burnett, Charles E Mahan, Sara R Vazquez, Lynn B Oertel, David A Garcia, Jack Ansell
Venous thromboembolism (VTE) is a serious medical condition associated with significant morbidity and mortality, and an incidence that is expected to double in the next forty years. The advent of direct oral anticoagulants (DOACs) has catalyzed significant changes in the therapeutic landscape of VTE treatment. As such, it is imperative that clinicians become familiar with and appropriately implement new treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance for VTE treatment with the DOACs...
January 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/26713281/monitoring-anticoagulant-therapy-with-new-oral-agents
#10
REVIEW
Allan Ramos-Esquivel
Thromboembolic disease is a major leading cause of mortality and morbidity in industrialized countries. Currently, the management of these patients is challenging due to the availability of new drugs with proven efficacy and security compared to traditional oral vitamin K antagonists. These compounds are characterized by a predictable pharmacokinetic profile for which blood monitoring is not routinely needed. Nevertheless, some data have suggested inter-patient variability in the anticoagulant effect of these drugs, raising concerns about their effectiveness and safety...
December 26, 2015: World Journal of Methodology
https://www.readbyqxmd.com/read/23861512/use-and-associated-risks-of-concomitant-aspirin-therapy-with-oral-anticoagulation-in-patients-with-atrial-fibrillation-insights-from-the-outcomes-registry-for-better-informed-treatment-of-atrial-fibrillation-orbit-af-registry
#11
Benjamin A Steinberg, Sunghee Kim, Jonathan P Piccini, Gregg C Fonarow, Renato D Lopes, Laine Thomas, Michael D Ezekowitz, Jack Ansell, Peter Kowey, Daniel E Singer, Bernard Gersh, Kenneth W Mahaffey, Elaine Hylek, Alan S Go, Paul Chang, Eric D Peterson
BACKGROUND: The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear. We assessed concomitant ASA use and its association with clinical outcomes among AF patients treated with OAC. METHODS AND RESULTS: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry enrolled 10 126 AF patients from 176 US practices from June 2010 through August 2011. The study population was limited to those on OAC (n=7347)...
August 13, 2013: Circulation
https://www.readbyqxmd.com/read/26715651/a-call-to-reduce-the-use-of-bridging-anticoagulation
#12
Adam J Rose, Arthur L Allen, Tracy Minichello
Because of the recent publication of several important studies, there has been a major change in how we think about perioperative management of anticoagulation. Because of these changes, existing consensus guidelines are suddenly out of date and can no longer be used as is, particularly the 2012 American College of Chest Physicians Antithrombotic Guidelines, version 9. We estimate that well over 90% of patients receiving warfarin therapy should not receive bridging anticoagulation during periprocedural interruptions of therapy, except under unusual circumstances and with appropriate justification...
January 2016: Circulation. Cardiovascular Quality and Outcomes
https://www.readbyqxmd.com/read/26717376/stroke-event-rates-and-the-optimal-antithrombotic-choice-of-patients-with-paroxysmal-atrial-fibrillation-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#13
REVIEW
Yicong Chen, Yuhui Zhao, Ge Dang, Fubing Ouyang, Xinran Chen, Jinsheng Zeng
The risks of stroke or systemic embolism and major bleeding are considered similar between paroxysmal and sustained atrial fibrillation (AF), and warfarin has demonstrated superior efficacy to aspirin, irrespective of the AF type. However, with the advent of novel oral anticoagulants (NOACs) and antiplatelet agents, the optimal antithrombotic prophylaxis for paroxysmal AF remains unclear.We searched Medline, Embase, CENTRAL, and China Biology Medicine up to October week 1, 2015. Randomized controlled trials of AF patients assigned to NOACs, warfarin, or antiplatelets, with reports of outcomes stratified by the AF type, were included...
December 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/26717378/risk-factors-for-bleeding-in-hospitalized-at-risk-patients-with-an-inr-of-5-or-more-treated-with-vitamin-k-antagonists
#14
Sophie Liabeuf, Lucie-Marie Scaltieux, Kamel Masmoudi, Bertrand Roussel, Julien Moragny, Michel Andrejak, Valérie Gras-Champel
Various predictive scores for vitamin K antagonist (VKA)-related bleeding have been developed and validated in outpatients and in patients treated for specific indications (when VKAs are used under optimal therapeutic conditions). However, there are few published data on the evaluation of bleeding risk factors in hospitalized, at-risk patients (with a high international normalized ratio [INR]) treated with VKAs. The objective of the present study was to identify the most relevant bleeding risk factors in 906 VKA-treated patients with an INR of 5 or more hospitalized in a French university medical center...
December 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/26718518/outcomes-of-patients-with-acute-myocardial-infarction-undergoing-percutaneous-coronary-intervention-receiving-an-oral-anticoagulant-and-dual-antiplatelet-therapy-a-comparison-of-clopidogrel-versus-prasugrel-from-the-translate-acs-study
#15
RANDOMIZED CONTROLLED TRIAL
Larry R Jackson, Christine Ju, Marjorie Zettler, John C Messenger, David J Cohen, Gregg W Stone, Brian A Baker, Mark Effron, Eric D Peterson, Tracy Y Wang
OBJECTIVES: The purpose of this study was to determine whether bleeding risk varies depending on which P2Y12 receptor inhibitor agent is used. BACKGROUND: Prior studies have shown significant bleeding risk among patients treated with triple therapy (i.e., oral anticoagulant, P2Y12 receptor inhibitor, and aspirin). METHODS: We evaluated patients with acute myocardial infarction (MI) treated with percutaneous coronary intervention (PCI) at 233 hospitals in the United States enrolled in the TRANSLATE-ACS (Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) study (April 2010 to October 2012)...
December 21, 2015: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/26727005/non-vitamin-k-oral-anticoagulants-versus-warfarin-for-patients-with-atrial-fibrillation-absolute-benefit-and-harm-assessments-yield-novel-insights
#16
REVIEW
Cyrus R Kumana, Bernard M Y Cheung, David C W Siu, Hung-Fat Tse, Ian J Lauder
BACKGROUND AND OBJECTIVES: Benefits and/or harms (including costs) of non-vitamin K oral anticoagulants (NOACs) versus warfarin therapy need appreciation in relative and absolute terms. METHODS: Accordingly, we derived clinically relevant relative and absolute benefit/harm parameters for NOACs (apixaban, dabigatran, rivaroxaban, edoxaban) compared to warfarin from four clinical trials involving atrial fibrillation (AF) patients. For each trial, we tabulated patient numbers enduring four important outcomes and calculated unadjusted relative risk reduction (RRR) and number needed to treat (NNT)/year values (and 95% confidence intervals) for the NAOC compared to warfarin...
April 2016: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/26729187/prevention-and-treatment-of-venous-thromboembolism-in-patients-with-cancer-focus-on-drug-therapy
#17
Nick van Es, Suzanne M Bleker, Ineke T Wilts, Ettore Porreca, Marcello Di Nisio
Venous thromboembolism (VTE) is a frequent complication in patients with cancer and is associated with significant morbidity and mortality. The use of anticoagulants for the prevention and treatment of VTE in this population is challenging given the high risk of both recurrent VTE and bleeding complications. Thromboprophylaxis with subcutaneous low-molecular-weight heparin (LMWH) is recommended in cancer patients hospitalized for an acute medical illness and in those undergoing major surgery. In ambulatory cancer patients with or without central venous catheters, routine thromboprophylaxis is not recommended because of the relatively low benefit-to-risk ratio...
March 2016: Drugs
https://www.readbyqxmd.com/read/26729693/risk-of-death-and-stroke-associated-with-anticoagulation-therapy-after-mitral-valve-repair
#18
MULTICENTER STUDY
Nana Valeur, Charlotte Mérie, Morten Lock Hansen, Christian Torp-Pedersen, Gunnar H Gislason, Lars Kober
OBJECTIVE: Guidelines generally recommend oral anticoagulation to be considered the first 3 months after mitral valve repair based on small studies and consensus. However, in several studies no benefit of anticoagulation has been found. METHODS: From the national registries we identified all Danish patients who underwent mitral valve repair during the period between 1997 and 2012. Medication, hospitalisation and mortality data were studied. The association of use of vitamin K antagonists (VKAs) at discharge and risk of stroke/death was evaluated by means of Cox regression, landmark analyses and propensity matched models...
May 2016: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/26731290/anticoagulation-for-prosthetic-heart-valves-unresolved-questions-requiring-answers
#19
REVIEW
Bobby Yanagawa, Richard P Whitlock, Subodh Verma, Bernard J Gersh
PURPOSE OF REVIEW: The efficacy of anticoagulation for valvular prostheses is the result of a delicate balance between the risk of thromboembolic (TE) events and bleeding. Here, we review data on anticoagulation for valve prostheses with a focus on clinical trials that address key unanswered questions. RECENT FINDINGS: There are several unanswered questions in the field of prosthetic valve anticoagulation, including: optimal TE prophylaxis in the short term for bioprostheses, optimal TE prophylaxis following transcatheter aortic valve implantation, the safety and efficacy of lower levels of anticoagulation with the bileaflet mechanical prosthesis, the role of aspirin for patients with mechanical prostheses, and the management of anticoagulation for mechanical valves in pregnancy...
March 2016: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/26598101/possible-rivaroxaban-failure-during-the-postpartum-period
#20
Kelly M Rudd, Amanda R McFee Winans, Narmadha Panneerselvam
Rivaroxaban, a factor Xa inhibitor, is a direct-acting oral anticoagulant (DOAC) indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for reducing the risk of DVT and PE recurrence. To our knowledge, no data are presently available to guide DOAC dosing in the postpartum period when pharmacokinetic and pharmacodynamic changes induced by pregnancy have an impact on drug clearance and increase hypercoagulability for a period of 6-8 weeks after delivery. We describe the case of a 35-year-old postpartum woman who presented to the emergency department with a diagnosis of a new multiple segmental PE 5 days after starting rivaroxaban therapy for a diagnosis of DVT...
November 2015: Pharmacotherapy
label_collection
label_collection
2840
1
2
2016-01-12 23:41:26
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"